Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05949294 | Withdrawn Phase 1 FDA Drug

• 2 other identifiers: AROSOD1-10012023-509032-26
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

In this Phase 1 adult symptomatic patients with amyotrophic lateral sclerosis (ALS) carrying a superoxide dismutase 1 (SOD1) gene mutation thought to be causative of ALS, will receive single ascending doses of ARO-SOD1 administered by intrathecal (IT) infusion. The study is primarily intended to evaluate safety, but will also evaluate the effect of ARO-SOD1 on SOD1 cerebrospinal fluid (CSF) levels as a biomarker of pharmacodynamic (PD) effect, therefore lumbar punctures will be required at timepoints throughout the study. After each participant has completed their individual final visit, participants whose SOD1 CSF levels have recovered to a satisfactory level may rescreen and enroll into higher dose cohorts; or if unable or unwilling to rescreen may enroll into an open-label study to be added by amendment when supported by nonclinical data for multidose administration.

Conditions

Amyotrophic Lateral Sclerosis

Outcome Measures

Primary Outcomes (1)

• Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

  From first dose of study drug through the end of study (EOS; up to 168 days)

Secondary Outcomes (15)

• Change Over Time from Baseline in CSF SOD1 Protein Levels

  Pre-dose on Day 1 (Baseline) through EOS (up to 168 days)

• Change Over Time from Baseline in Plasma Levels of Neurofilament Light Chain (NfL)

  Pre-dose on Day 1 (Baseline) through EOS (up to 168 days)

• Pharmacokinetics (PK) of ARO-SOD1: Maximum Observed Plasma Concentration (Cmax)

  Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours

• PK of ARO-SOD1: Time to Reach Maximum Observed Plasma Concentration (Tmax)

  Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours

• PK of ARO-SOD1: Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24)

  Days 1, 2, 15, 29, 57, 85 and EOS (Day 168): Pre-dose, post-dose at 1, 3, 5, 7, 12 and 24 hours

Study Arms (1)

ARO-SOD1

EXPERIMENTAL

ARO-SOD1 Injection

Drug: ARO-SOD1 Injection

Interventions

ARO-SOD1 Injection DRUG

single doses of ARO-SOD1 Injection by IT infusion

ARO-SOD1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of ALS based on source-verifiable medical record and meets the Gold Coast Criteria
• Pathogenic or likely pathogenic SOD1 mutation based on source-verifiable medical records or genetic testing during Screening
• Slow Vital Capacity (SVC) ≥ 50% of predicted value adjusted for sex, age, and height (from a sitting position) at Screening
• Body Mass Index (BMI) ≥ 18.0 kg/m2 at Screening
• Able to complete at least 6 months of follow-up
• If taking any medication or supplement to treat ALS or ALS symptoms, must be on stable dose for ≥ 4 weeks prior to Day 1 and expected to remain at that dose until final study visit and not expected to start these medications after the first dose of ARO-SOD1
• Able and willing to provide written informed consent and to comply with all study assessments
• Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last dose of study drug, whichever is later. Males must not donate sperm and females must not donate eggs during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later.

You may not qualify if:

• Current or anticipated need of a diaphragm pacing system (DPS) during the study
• Participants using tofersen can be enrolled only after a washout period of approximately 20 weeks from the last tofersen dose to the first planned dose of ARO-SOD1
• History of having received stem cell therapy for ALS treatment
• Any current or anticipated contraindications to lumbar puncture (LP)
• The presence of an implanted shunt for drainage of CSF or an implanted central nervous system (CNS) catheter
• Human immunodeficiency virus (HIV), seropositive for hepatitis B virus (HBV), seropositive for hepatitis C virus (HCV)
• Uncontrolled hypertension
• Severe cardiovascular disease
• History of drug abuse or alcoholism within 6 months of study enrollment
• Inability to comply with study requirements

Sponsors & Collaborators

• Arrowhead Pharmaceuticals: lead

MeSH Terms

Conditions

Amyotrophic Lateral Sclerosis

Condition Hierarchy (Ancestors)

Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Motor Neuron Disease; Neurodegenerative Diseases; TDP-43 Proteinopathies; Neuromuscular Diseases; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2023
• First Posted: July 18, 2023
• Study Start: January 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2025
• Last Updated: April 17, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share